CD122 CD132 Reporter Cell Line

Description

Interleukin-2 (IL-2) is a key growth factor for tumor-infiltrating lymphocytes, mainly expressed by activated T cells in response to recognizing homologous antigens. While IL-2 promotes the proliferation and survival of activated effector cells and naive T cells, it also activates regulatory T cells (Tregs).The activity of IL-2 mainly occurs through binding to IL-2 receptors on the surface of lymphocytes and transmitting signals intracellularly. The IL-2 receptor is a heterotrimer composed of α, β, and γ subunits (IL-2Rα/CD25, IL-2Rβ/CD122, IL-2Rγ/CD132).IL-2Rγ/CD132 is expressed on all lymphocytes, while IL-2Rβ/CD122 is constitutively expressed on natural killer (NK) cells and CD8 memory T cells, and can be induced on naive T cells after antigen recognition. IL-2Rγ/CD132 and IL-2Rβ/CD122 are subunits involved in intracellular signal transduction, while IL-2Rα/CD25 does not participate in signal transduction.At low concentrations, IL-2 preferably binds to high-affinity trimeric complex receptors (IL2Rαβγ) constitutively expressed on Tregs, thus low-dose IL-2 can activate Tregs to induce immune tolerance, used in the treatment of autoimmune diseases such as type 1 diabetes and lupus. High concentrations of IL-2, after saturating Tregs, will bind to moderate-affinity dimeric complex receptors (IL2Rβγ) constitutively expressed on NK cells and CD8+ T cells, activating them to increase anti-cancer activity. When IL-2 binds to IL-2Rα/CD25 subunit alone, its affinity is only one percent of the trimeric complex receptor (IL2Rαβγ). Therefore, different research companies have explored different design approaches based on different application scenarios, including PEG modification, Fc fusion, mutant design, bispecific antibody design, and combination immunotherapy strategies.AcceGen has developed CD122 CD132 Reporter Cell Line with low IL-2Rα/CD25 receptor expression and CD25 CD122 CD132 Reporter Cell Line with high IL-2Rα/CD25 receptor expression. Upon IL-2 binding to the receptor, downstream signaling pathways are activated, leading to the expression of firefly luciferase. Luciferase readout reflects the activation effect of the signaling pathway, making it useful for in vitro evaluation of IL-2 and related drugs targeting its receptor.